PuSH - Publikationsserver des Helmholtz Zentrums München: Photodynamic diagnosis of early stage malignancies: preliminary results in urology and pneumonology.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Baumgartner, R. ; Kriegmair, M. ; Jocham, D. ; Hofstetter, A.G. ; Huber, R.M. ; Karg, O. ; Haeußinger, K.

Photodynamic diagnosis of early stage malignancies: preliminary results in urology and pneumonology.

Proc. SPIE 1641, 107-112 (1992)

DOI

Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.

Abstract
Metriken
Zusatzinfos

On the basis of clinical protocols, phase II-studies have been started to evaluate photodynamic diagnosis for early visualization o cancer in bladder and lung. As tumor marker the fluorescent and photosensitizing polyporphyrin Photofrin II is used in a dose which has been proven to avoid photosensitization of the patients' skin. The drug is administered systemically in a concentration of mostly 0,4 mg/kg body weight. Fluorescence of Photofrin II in tissue is detected by an image-intensifying CCD camera coupled to endoscopes usually used in both medical disciplines. Video presentation of the marker fluorescence occurs with high contrast due to real-time image processing following two-wavelength excitation of the tissue with laser light. A keypoint of the new diagnostic method is the correlation of the fluorescence contrast and the histological examination of biopsies removed from these areas. As an examples, 87 biopsies have been taken from 17 patients suffering from bladder cancer. While all tumorous samples (n = 16) show strong fluorescence, about 30% of the biopsies are judged as false positive. A variety of premalignant diseases has been found in these sections. No false negative results have been obtained up to now.

Impact Factor

Scopus SNIP

Altmetric

0.000